NJ State Employees Deferred Compensation Plan continued to hold its position in shares of Forward Pharma A/S (NASDAQ:FWP) during the second quarter, Holdings Channel reports. The institutional investor owned 15,000 shares of the biotechnology company’s stock at the end of the second quarter. NJ State Employees Deferred Compensation Plan’s holdings in Forward Pharma A/S were worth $305,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of FWP. Baupost Group LLC MA increased its stake in shares of Forward Pharma A/S by 3.9% in the first quarter. Baupost Group LLC MA now owns 5,575,407 shares of the biotechnology company’s stock worth $119,927,000 after buying an additional 208,107 shares during the last quarter. Eqis Capital Management Inc. increased its stake in shares of Forward Pharma A/S by 25.5% in the second quarter. Eqis Capital Management Inc. now owns 20,178 shares of the biotechnology company’s stock worth $410,000 after buying an additional 4,097 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Forward Pharma A/S during the first quarter worth $269,000. Marshall Wace North America L.P. acquired a new stake in shares of Forward Pharma A/S during the first quarter worth $612,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Forward Pharma A/S during the first quarter worth $2,465,000. Institutional investors own 22.33% of the company’s stock.

Shares of Forward Pharma A/S (NASDAQ:FWP) opened at 24.10 on Thursday. Forward Pharma A/S has a one year low of $14.89 and a one year high of $33.00. The firm has a 50-day moving average price of $21.81 and a 200-day moving average price of $23.38. The company’s market capitalization is $1.14 billion.

ILLEGAL ACTIVITY WARNING: “Forward Pharma A/S (FWP) Stake Maintained by NJ State Employees Deferred Compensation Plan” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/10/forward-pharma-as-fwp-stake-maintained-by-nj-state-employees-deferred-compensation-plan.html.

A number of equities research analysts have weighed in on FWP shares. ValuEngine upgraded Forward Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday, June 17th. BidaskClub upgraded Forward Pharma A/S from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Finally, Jefferies Group LLC set a $22.00 target price on Forward Pharma A/S and gave the stock a “hold” rating in a report on Tuesday, April 18th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Forward Pharma A/S currently has a consensus rating of “Hold” and an average price target of $24.00.

About Forward Pharma A/S

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Want to see what other hedge funds are holding FWP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Forward Pharma A/S (NASDAQ:FWP).

Institutional Ownership by Quarter for Forward Pharma A/S (NASDAQ:FWP)

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.